Hims & Hers Health, Inc. $HIMS Stock Holdings Increased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 62.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,600 shares of the company’s stock after acquiring an additional 40,186 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Hims & Hers Health were worth $5,214,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in HIMS. Bessemer Group Inc. raised its stake in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the 1st quarter valued at $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health during the 1st quarter valued at $41,000. Larson Financial Group LLC raised its stake in shares of Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after buying an additional 458 shares in the last quarter. Finally, Webster Bank N. A. raised its stake in shares of Hims & Hers Health by 229.1% in the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after buying an additional 630 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 0.8%

Shares of Hims & Hers Health stock opened at $48.40 on Tuesday. The stock’s fifty day moving average is $51.20 and its 200-day moving average is $49.94. The firm has a market capitalization of $10.94 billion, a PE ratio of 60.50, a price-to-earnings-growth ratio of 3.38 and a beta of 2.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 12-month low of $18.33 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the firm earned $0.06 earnings per share. The firm’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock in a transaction on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer owned 128,984 shares in the company, valued at $7,139,264.40. This represents a 52.92% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,429,634 shares of company stock worth $74,097,471. 17.71% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HIMS. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Canaccord Genuity Group reissued a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. KeyCorp began coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Finally, Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.